EXPRESSION OF ESTROGEN-RECEPTOR VARIANTS IN NORMAL AND NEOPLASTIC HUMAN UTERUS

Citation
Cz. Hu et al., EXPRESSION OF ESTROGEN-RECEPTOR VARIANTS IN NORMAL AND NEOPLASTIC HUMAN UTERUS, Molecular and cellular endocrinology, 118(1-2), 1996, pp. 173-179
Citations number
42
Categorie Soggetti
Endocrynology & Metabolism","Cell Biology
ISSN journal
03037207
Volume
118
Issue
1-2
Year of publication
1996
Pages
173 - 179
Database
ISI
SICI code
0303-7207(1996)118:1-2<173:EOEVIN>2.0.ZU;2-Z
Abstract
Estrogen receptor variants lacking internal exons and representing dom inant positive and negative activity may be involved in the initiation and/or progression of endocrine dependent tumors. To assess the role of estrogen receptor in uterine disease, we have analyzed both normal and neoplastic uterine samples for the presence of variant estrogen re ceptors using the sensitive technique of RT-PCR and direct automated D NA sequencing of the amplified products. Our analysis was conducted to determine the presence of spliced variants lacking exons 3 through ex on 8. We demonstrate that both the normal and neoplastic human uterus contains a number of spliced variants of the estrogen receptor that co -exist with the wild type receptor. Variants lacking exons 4, 5 and 7 but not exons 3 and 6 were detected. Also, a novel partial deletion in exon 8 was detected in both the normal and neoplastic tissues, althou gh a total deletion of this exon was not observed. In addition another region of exon 8 deletion was found to be present in one tumor tissue which also contained an insertion within this region, however, other tumors did not contain this variant. In addition, double exon deletion variants were observed lacking exons 3 and 4, exons 4 and 5, and exon 7 with part of exon 8. Although our data represents a limited number of samples it suggests that splicing of the estrogen receptor message occurs in the normal physiological setting. There does not appear to b e any association between the presence or absence of spliced variants of estrogen receptor and uterine tumor formation at the mRNA level.